Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 6 minute read Pharma Industry News NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough? NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next. bySrinathNovember 24, 2025